| [1] |
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2015 annual data report: liver[J]. Am J Transplant, 2017, 17 Suppl 1:174-251.
|
| [2] |
Colvin M, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 annual data report: heart[J]. Am J Transplant, 2017, 17 Suppl 1:286-356.
|
| [3] |
Valapour M, Skeans MA, Smith JM, et al. OPTN/SRTR 2015 annual data report: lung[J]. Am J Transplant, 2017, 17 Suppl 1:357-424.
|
| [4] |
Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 annual data report:kidney[J]. Am J Transplant, 2017, 17 Suppl 1:21-116.
|
| [5] |
Beck J, Bierau S, Balzer S, et al. Digital droplet PCR for rapid quantification of donor DNA in the circulation of transplant recipients as a potential universal biomarker of graft injury[J]. Clin Chem, 2013, 59(12):1732-1741.
|
| [6] |
Jahr S, Hentze H, Englisch S, et al. DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells[J]. Cancer Res, 2001, 61(4):1659-1665.
|
| [7] |
Sigdel TK, Vitalone MJ, Tran TQ, et al. A rapid noninvasive assay for the detection of renal transplant injury[J]. Transplantation, 2013, 96(1):97-101.
|
| [8] |
Gadi VK, Nelson JL, Boespflug ND, et al. Soluble donor DNA concentrations in recipient serum correlate with pancreas-kidney rejection[J]. Clin Chem, 2006, 52(3):379-382.
|
| [9] |
Grskovic M, Hiller DJ, Eubank LA, et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients[J]. J Mol Diagn, 2016, 18(6):890-902.
|
| [10] |
Kanzow P, Kollmar O, Schütz E, et al. Graft-derived cell-free DNA as an early organ integrity biomarker after transplantation of a marginal HELLP syndrome donor liver[J].Transplantation, 2014, 98(5):e43-45.
|
| [11] |
Macher HC, Suárez-Artacho G, Guerrero JM, et al. Monitoring of transplanted liver health by quantification of organ-specific genomic marker in circulating DNA from receptor[J]. PLoS One, 2014, 9(12):e113987.
|
| [12] |
Beck J, Oellerich M, Schulz U, et al. Donor-derived cell-free DNA is a novel universal biomarker for allograft rejection in solid organ transplantation[J]. Transplant Proc, 2015, 47(8):2400-2403.
|
| [13] |
Zhang J, Tong KL, Li PK, et al. Presence of donor- and recipient-derived DNA in cell-free urine samples of renal transplantation recipients: urinary DNA chimerism[J]. Clin Chem, 1999, 45(10):1741-1746.
|
| [14] |
De Vlaminck I, Martin L, Kertesz M, et al. Noninvasive monitoring of infection and rejection after lung transplantation[J]. Proc Natl Acad Sci USA, 2015, 112(43):13336-13341.
|
| [15] |
Oellerich M, Schütz E, Kanzow P, et al. Use of graft-derived cell-free DNA as an organ integrity biomarker to reexamine effective tacrolimus trough concentrations after liver transplantation[J]. Ther Drug Monit, 2014, 36(2):136-140.
|
| [16] |
Rodríguez-Perálvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate/severe acute rejection and long-term outcome[J]. J Hepatol, 2013, 58(2):262-270.
|
| [17] |
Londoño MC, Danger R, Giral M, et al. A need for biomarkers of operational tolerance in liver and kidney transplantation[J]. Am J Transplant, 2012, 12(6):1370-1377.
|
| [18] |
Oellerich M, Walson PD, Beck J, et al. Graft-derived cell-free DNA as a marker of transplant graft injury[J]. Ther Drug Monit, 2016, 38 Suppl 1:S75-79.
|
| [19] |
De Vlaminck I, Khush KK, Strehl C, et al. Temporal response of the human virome to immunosuppression and antiviral therapy[J]. Cell, 2013, 155(5):1178-1187.
|